Clinical Trial Update: Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients [Phase 3]

View source ↗

Summary

A Phase 3 extension study evaluating safety and efficacy of Mylan's insulin glargine (Lantus) in adults with Type 1 diabetes has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin glargine (Mylan) (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Mylan Inc. | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2020-09-14